Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

United Therapeutic (UTHR)

United Therapeutic (UTHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

United Therapeutic 1000 SPRING ST SILVER SPRING MD 20910 USA

www.unither.com Employees: 1,305 P: 301-608-9292

Sector:

Medical

Description:

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.

Key Statistics

Overview:

Market Capitalization, $K 20,708,690
Enterprise Value, $K 19,311,490
Shares Outstanding, K 43,057
Annual Sales, $ 2,877 M
Annual Net Income, $ 1,195 M
Last Quarter Sales, $ 799,500 K
Last Quarter Net Income, $ 338,700 K
EBIT, $ 1,494 M
EBITDA, $ 1,566 M
60-Month Beta 0.86
% of Insider Shareholders 10.30%
% of Institutional Shareholders 94.08%
Float, K 38,622
% Float 89.70%
Short Volume Ratio 0.63

Growth:

1-Year Return 29.30%
3-Year Return 72.63%
5-Year Return 249.03%
5-Year Revenue Growth 98.61%
5-Year Earnings Growth 1,130.96%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 7.16 on 10/29/25
Next Earnings Date N/A
Earnings Per Share ttm 26.39
EPS Growth vs. Prev Qtr 11.70%
EPS Growth vs. Prev Year 12.05%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 09/23/09

UTHR Ratios

Ratio
Price/Earnings ttm 17.97
Price/Earnings forward 17.61
Price/Earnings to Growth 4.71
Return-on-Equity % 18.83%
Return-on-Assets % 16.75%
Profit Margin % 41.53%
Debt/Equity 0.00
Price/Sales 7.09
Price/Cash Flow 16.70
Price/Book 3.10
Book Value/Share 153.05
Interest Coverage 36.87
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar